Methyldopa

规格

555-30-6CAS 号

209-089-2EC 号

(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acidIUPAC 名称

C10H13NO4化学式

211.21 g/mol分子量

methyldopa; 555-30-6; Alphamethyldopa; Dopamet; Presolisin; Medomet; Alpha medopa; l-alpha-Methyldopa; Methyldopa anhydrous; Aldometil; Methoplain; Sedometil; Dopatec; Hyperpax; Methyl dopa; alpha-Methyl dopa; Sembrina; Hypolag; Dopegyt; Medopren; Presinol; alpha-Methyl-L-dopa; L-Methyl Dopa; Metildopa; L-(alpha-Md); Methyl-L-dopa; Methyldopum; Dopegit; (S)-(-)-alpha-Methyldopa; Bayer 1440 L; 3-Hydroxy-alpha-methyl-L-tyrosine; Aldomin; L-Methyldopa; Anhydrous methyldopa; Lederdopa; alpha-Methyldihydroxyphenylalanine; l-3-(3,4-Dihydroxyphenyl)-2-methylalanine; alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; Methyldopa, anhydrous; BAYER-1440L; (-)-alpha-methyldopa; levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; L-Tyrosine, 3-hydroxy-alpha-methyl-; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; J9.247I; M4R0H12F6M; CHEBI:61058; MK-351; Nr.C 2294; NSC-169916; NSC-760080; MK 351; Alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, L-(-)-; NCI-C55721; NSC169916; Dopergit; (2S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-2-methylpropanoate; Amodopa; Apo Methyldopa; alpha Methyldopa; Nu Medopa; Metalpha 250; Metalpha 500; methyldopate (ester); alpha Methyl L Dopa; RefChem:6032; C02AB01; methyldopate hydrochloride (ester); 209-089-2; 56LH93261Y; Baypresol; Aldomet; L-(-)-alpha-Methyldopa; L-alpha-Methyl DOPA; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; (S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (-)-Methyldopa; Dopamethyperpax; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; Grospisk; Becanta; Medopal; Carbidopa EP Impurity A; Methyldopa [INN]; Methyldopa (L,-); Methyldopa (Levorotatory); Methyldopa (INN); 88620-56-8; DTXSID5023295; MK-351;Methyldopa; Aldomet (TN); (-)-.alpha.-Methyldopa; AMD; MLS000028644; 3-(3,4-Dihydroxyphenyl)-2-methyl-L-alanine sesquihydrate; L-.alpha.-Methyldopa; Novomedopa; SMR000059170; .alpha.-Methyl-L-dopa; Apo-Methyldopa; Nu-Medopa; L-Tyrosine, 3-hydroxy-.alpha.-methyl-; Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; (S)-(-)-.alpha.-Methyldopa; a-methyl-l-dopa; alpha-Methyl-L-dopa sesquihydrate; Methyldopa (anhydrous); (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic acid; MFCD00004186; 3-Hydroxy-.alpha.-methyl-L-tyrosine; phenylalanine, alpha-methyl-3,4-dihydroxy-; CCRIS 4671; HSDB 218; SR-01000597712; EINECS 209-089-2; NSC 169916; UNII-M4R0H12F6M; Medoba; l-a-methyldopa; a-methyl dopa; Tyrosine, 3-hydroxy-.alpha.-methyl-; 3,4-Dihydroxy-2-methylphenylalanine #; CAS-555-30-6; Prestwick_732; (-)-a-methyldopa; a-methyldopa (van); .alpha.-Methyl-L-3,4-dihydroxyphenylalanine; Methyldopa 250 Tab; L-(-)--Methyldopa; L(-)-a-methylalanine; Spectrum_000937; Tocris-0584; MK-351; Methyldopa; METHYLDOPA [MI]; Nu-Medopa Tab 125mg; Nu-Medopa Tab 250mg; Nu-Medopa Tab 500mg; L-(-)-?-Methyldopa; Novo-Medopa Tab 125mg; Novo-Medopa Tab 250mg; Novo-Medopa Tab 500mg; Prestwick0_000326; Prestwick1_000326; Prestwick2_000326; Prestwick3_000326; Spectrum2_001068; Spectrum3_000501; Spectrum4_000054; Spectrum5_001295; L-(-)-|A-Methyldopa; METHYLDOPA [HSDB]; (s)-(-)-a-methyldopa; L(-)-alpha-methylalanine; CHEMBL459; Epitope ID:146097; L-(-)- alpha-Methyldopa; Apo Methyldopa Tab 125mg; Apo Methyldopa Tab 250mg; Apo Methyldopa Tab 500mg; METHYLDOPA [WHO-DD]; L-(a-MD); Lopac0_000853; SCHEMBL34003; BSPBio_000331; BSPBio_002021; KBioGR_000547; KBioSS_001417; cid_38853; MLS006011978; BIDD:GT0620; DivK1c_000142; Methyldopa 125 Tab 125mg; Methyldopa 500 Tab 500mg; SPECTRUM1500403; SPBio_001056; SPBio_002252; BPBio1_000365; DTXCID403295; GTPL5217; orb1224680; orb1310547; SCHEMBL29352376; BDBM48449; HMS500H04; KBio1_000142; KBio2_001417; KBio2_003985; KBio2_006553; KBio3_001521; NINDS_000142; GLXC-08142; HMS1569A13; HMS1920N09; HMS2090B11; HMS2091F04; HMS2096A13; HMS2235N11; HMS3262L07; HMS3372J14; HMS3411G18; HMS3675G18; HMS3713A13; HMS3887I15; Pharmakon1600-01500403; L-(-)-a-methyl-a-methyl-Aldomin; HY-B0225; MSK10652; Tox21_202610; Tox21_500853; ANHYDROUS METHYLDOPA [MART.]; CCG-40120; DL-443; EBC-03598; HB1822; NSC760080; a-Methyl-L-3,4-dihydroxyphenylalanine; AKOS015960582; AC-8431; DB00968; FM31922; KS-1424; LP00853; SDCCGSBI-0050829.P002; IDI1_000142; NCGC00024667-01; NCGC00024667-02; NCGC00024667-03; NCGC00024667-05; NCGC00024667-06; NCGC00024667-07; NCGC00024667-08; NCGC00024667-09; NCGC00024667-10; NCGC00024667-11; NCGC00024667-13; NCGC00024667-21; NCGC00024667-26; NCGC00260158-01; NCGC00261538-01; AC-11671; AS-13052; L-(-)-alpha-methyl-alpha-methyl-Aldomin; CARBIDOPA IMPURITY A [EP IMPURITY]; L-a-Methyl-(3, 4-dihydroxyphenyl)alanine; DB-222797; D1817; EU-0100853; NS00007484; L-alpha-Methyl-(3, 4-dihydroxyphenyl)alanine; C07194; D08205; D82313; EN300-120685; AB00052043_09; AB01275508-01; AB01275508_02; Q412621; L-(-)-3-(3,4-dihydroxyphenyl)-2-methyl-Alanine; SR-01000597712-1; SR-01000597712-3; 3,4-dihydroxy-2-methylphenylalanine (ACD/Name 4.0); BRD-K48578705-001-14-3; BRD-K48578705-001-15-0; BRD-K48578705-001-16-8; BRD-K48578705-001-17-6; (-)-.ALPHA.-METHYL-3,4-DIHYDROXYPHENYLALANINE; L-.ALPHA.-METHYL-3-(3,4)-DIHYDROXYPHENYLALANINE; Z1508915075; (S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoicacid; Methyldopa, European Pharmacopoeia (EP) Reference Standard; Methyldopa, United States Pharmacopeia (USP) Reference Standard; 3-(3,4-Dihydroxyphenyl)-2-methyl-L-alanine (H-L-aMeTyr(3-OH)-OH); Methyldopa for system suitability, European Pharmacopoeia (EP) Reference Standard; 27289-76-5; 3-(3,4-Dihydroxyphenyl)-<span class='symbol'>alpha</span>-methyl-<span class='DL'>L</span>-a lanine同义词